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Abstract
Objectives: Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may
contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy
(OPAT) services.
Methods: We retrospectively reviewed the clinical efficacy and safety of CIs of meropenem in two Australian tertiary
hospitals and assessed its stability under simulated OPAT conditions including in elastomeric infusion devices containing 1%
(2.4 g) or 2% (4.8 g) concentrations at either ‘room temperature’ or ‘cooled’ conditions. Infusate aliquots were assayed at
different time-points over 24 hours.
Results: Forty-one (82%) of 50 patients had clinical improvement or were cured. Adverse patient outcomes including
hemato-, hepato- and nephrotoxicity were infrequent. Cooled infusers with 1% meropenem had a mean 24-hour recovery
of 90.3%. Recoveries of 1% and 2% meropenem at room temperature and 2% under cooled conditions were 88%, 83% and
87%, respectively. Patients receiving 1% meropenem are likely to receive .95% of the maximum deliverable dose (MDD)
over a 24-hour period whilst patients receiving 2% meropenem should receive 93% and 87% of the MDD under cooled and
room temperature conditions, respectively.
Conclusions: Meropenem infusers are likely to deliver ,95% MDD and maintain effective plasma concentrations
throughout the dosing period. These data reflect our local favourable clinical experience with meropenem CIs.
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Introduction
Administration of antibiotics by continuous infusions (CI) is a
practical method in outpatient parenteral antimicrobial therapy
(OPAT) settings. Ideally, drug stability should be maintained in
the CI device throughout the infusion period to ensure that the
patient receives sufficient active drug to achieve cure while
avoiding exposure to toxic degradation products. Although the
European and US Pharmacopoeias define infusion stability as the
maintenance of .90% of the initial concentration throughout the
infusion period, this may not necessarily apply for certain
medications and might limit therapeutic opportunities for these
drugs [1].
One such drug might be meropenem, a broad spectrum
carbapenem antibiotic that is increasingly required for the
treatment of severe infections caused by multi-resistant Gram-
negative bacteria [2]. Meropenem stability in solution depends on
infusion time, concentration and temperature. Significant degra-
dation is observed at higher ambient temperatures, when diluted
in normal saline and stored over 8 hours [3], in sealed vials over
24 hours at 25uC and 37uC, and in infusion devices at higher
concentrations (6.4%) stored at 37uC [3–6]. However, these
studies have also demonstrated improved stability at lower
concentrations (,4%) and ambient temperatures (,25uC) [4,7–9].
Uncertainty regarding the clinical impact of meropenem
stability is reflected by different practices across OPAT services
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internationally [10]. In Western Australian tertiary hospitals, we
have accumulated clinical experience using 24-hour CI of
meropenem in our OPAT services without evident safety or
efficacy concerns. In light of data demonstrating a lack of stability
of meropenem and variability in clinical CI use, we performed a
study with two components, namely a retrospective review of the
efficacy and safety of CI meropenem in our OPAT services, and
meropenem stability under simulated real-world conditions using
the infusion devices used by our OPAT service and at lower
concentrations than in previous studies.
Materials and Methods
Efficacy and safety review
The study setting was two large adult tertiary hospitals located
in a temperate region of Western Australia, where the annual
mean maximum and minimum temperatures are 24.7uC and
12.7uC, respectively [11]. All adult patients who received at least
one day of meropenem via 24-hour CI in our respective OPATs
between July 2008 and March 2013 were eligible for inclusion.
Patients typically received meropenem via intermittent dosing as
an inpatient before being switched to an outpatient 24-hour CI at
the same daily dose. Meropenem was delivered via a peripherally
inserted central catheter (PICC) using an elastomeric infuser
device prepared locally (LV10, Baxter Healthcare, Sydney,
Australia). The prescribed meropenem dose was reconstituted in
240 mL of 0.9% normal saline and delivered at 10 mL/h. Active
cooling of the infuser devices was not routinely performed. Patients
were reviewed by nurses daily, and had weekly physician review
together with weekly monitoring of hematologic, renal and hepatic
function. Case records of patients were reviewed to determine
demographics, co-morbidities, indication for antimicrobial thera-
py, duration and dose of meropenem, concomitant antimicrobials,
laboratory results and adverse events. Clinical outcome was
assessed at the completion of parenteral therapy and categorised as
follows: cure (completed OPAT therapy with resolution of
infection and no requirement for long term antibiotic therapy),
improved (complete OPAT therapy with partial resolution of
infection but need for further follow-up) or failure (progression or
non-response of infection despite OPAT, re-admission, surgical
intervention, or all cause death). We defined antibiotic-induced
neutropaenia, eosinophilia, thrombocytopaenia and anaemia as
the development of an absolute neutrophil count ,16109/L,
eosinophil count .0.56109/L, platelet count ,1506109/L and
haemoglobin ,100 g/L, respectively. Nephrotoxicity was defined
as a rise in creatinine of .50% from baseline [12]. Hepatotoxicity
was defined using US FDA criteria [13]. Approval from the South
Metropolitan Area Human Research Ethics Committees was
obtained for both study components. Patients recruited to the
stability study provided written, informed consent. For the
retrospective arm of the study, individual consent was not
obtained, but all records were anonymised and de-identified prior
to analysis.
Meropenem stability under simulated OPAT conditions
Meropenem trihydrate (Ranbaxy Australia Pty Ltd, North
Ryde, Australia) was reconstituted in normal saline and placed in
an elastomeric infuser device (LV10, Baxter Healthcare, Sydney,
Australia) at either 1% (2.4 g in 240 mL) or 2% (4.8 g in 240 mL)
w/v. These concentrations were chosen to be comparable to other
stability studies (using rounded up by % w/v) as well as being
within the median dose ranges that were given to the majority of
our patients. Infusers were refrigerated overnight and then
allocated to ‘room temperature’ or ‘cooled’ by placing them in a
standard carry-bag or a ‘cooler bag’ (Fridge-to-go, Interaction
Branding Pty Ltd, Frenchs Forest, Australia) with a puck-shaped
ice brick. Continuous temperature monitoring strips (TP138,
timestrip PLUS, Timestrip UK Ltd, London, UK) were placed on
the outside of each infuser as a semi-quantitative measure of the
time that each infuser spent above 20uC.
Volunteers carried the infusers around the waist or over the
shoulder for a 24-hour period to simulate real-world OPAT
conditions. This allowed ambient temperature to vary throughout
the day. Volunteers were also instructed to place the infusion
devices outside the bedclothes whilst sleeping. For ‘cooled’
infusers, the ice pucks were changed every 8 h.
Infusates were sampled at 0, 2, 4, 8, 14 and 24 hours by
allowing a small amount (,2 mL) to flow from the device before
collecting 1.5 mL for testing. Infusate aliquots were transported on
ice and stored at 280uC prior to analysis.
Meropenem (molecular weight [MW] = 437.51) was assayed by
liquid chromatography-mass spectroscopy (LC/MS) with ertape-
nem sodium (MW = 497.51) (Merck & Co. Inc, Rahway, USA) as
an internal standard (IS). Chromatographic separation was
performed on a GraceSmart RP 18 3 mm column
(100 mm62.1 mm i.d.) at ambient temperature. The autosampler
temperature was set at 4uC to protect sample degradation during
analysis. The retention times (RT) for meropenem and ertapenem
were 1.8 and 2.5 min, respectively. A 5-point linear calibration
curve (r2$0.99) was constructed by spiking meropenem into blank
0.9% w/v saline solution in a range of 0.01–0.05% w/v.
Stock solutions of meropenem and ertapenem, were prepared
separately and stored protected from light at 280uC. A 5-point
linear calibration curve (r2$0.99) was constructed by spiking
meropenem into blank 0.9% NaCl in a range of 0.01–0.05%.
Etrapenem IS (0.02%) was added to all samples. Infusor samples
were diluted 50 times with normal saline. The injection volume
was 1 mL and each sample was injected twice. Chromatographic
data (peak area ratio of meropenem:ertapenem) were processed
using LAB Solution (Version 5, Shimadzu, Japan). Assay intra-
and inter-day relative standard deviations were below 10% and
the limit of detection was 0.00001%.
Data were analysed using GraphPad Prism (version 5.0a).
Continuous variables were summarised as mean6SD or median
(interquartile range [IQR]) for parametric and non-parametric
data, respectively. Two-sample comparisons of continuous vari-
ables were by Student’s t-test and associations between normally-
distributed variables were assessed by Pearson’s correlation co-
efficient. The observed area under the concentration-time curve
(AUC) was calculated using the trapezoidal method. This value
was then divided by the theoretical maximum AUC (assuming no
degradation of meropenem), giving a percentage of the maximum
deliverable dose (MDD).
An illustrative simulation was then performed using previously
described meropenem population pharmacokinetic parameters
[14]. Stability data from the present study was incorporated into a
custom model (using ADVAN 6) where the input rate of
meropenem followed the reduction in concentration noted over
24 hours.
Combining this custom input model with the published
population pharmacokinetic model, median plasma meropenem
concentrations (as well as the 2.5th and 97.5th centiles, to provide a
95% prediction interval [PI95]) for 200 simulations of an average
70 kg adult male with normal renal function during a 7-day course
of meropenem given by CI were simulated using NONMEM
(version 7.2.0) and plotted against microbiological breakpoints for
Pseudomonas aeruginosa (4 mg/L) and Enterobacteriaceae (1 mg/L)
[15].
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Results
Efficacy and safety review
Fifty patients received CI of meropenem through our OPAT
services during the 6-year study period. The median age was 59
(range 18–91) years and 60% were male. Patients had a range of
infections including lower respiratory tract (n = 17), bone and/or
joint (n = 14), intra-abdominal (n = 6), diabetic foot (n = 4), urinary
tract (n = 3), otitis externa (n = 2) and other (n = 4). The most
prevalent co-morbidities were diabetes mellitus (n = 18), cardiac
disease (n = 13), chronic renal impairment (n = 11) and immuno-
suppression (n = 10). The most frequent primary pathogens were
P. aeruginosa (n = 30) and other Gram-negative organisms (n = 8),
and Nocardia species (n = 2) and Burkholderia pseudomallei (n = 1) were
also isolated. Infection was polymicrobial in 40% of cases. Twenty-
four patients (48%) received a second antibiotic for additional
activity against Gram-negative bacteria. These included fluoro-
quinolones (n = 12), aminoglycosides (n = 7), folate antagonists
(n = 4) and inhaled colistin (n = 1). The median duration of
meropenem therapy as an inpatient prior to OPAT was 7 (IQR
2.25–10, range 0–41) days and the median OPAT duration was 18
(IQR 9–29, range 4–81) days. The median total daily dose of
meropenem was 3 (IQR 3–3, range 1–6) g or 1.25 (range 0.42–
2.5)% w/v. Thirty-six patients had surgical debridement as part of
their inpatient management in addition to antibiotic therapy. For
most patients (92%), infusers were not actively cooled.
At completion of meropenem therapy, 8 patients (16%) were
cured, 33 (66%) had improved and 9 (18%) failed therapy. OPAT
CI with meropenem was ceased early in 5 patients (10%). A
meropenem-resistant isolate was identified in two of these cases,
while the remaining three were readmitted and CI with
meropenem interrupted due to dyspnoea, neutropaenia and
toxicity due to concomitant voriconazole, respectively.
Asymptomatic thrombocytopaenia and eosinophilia were ob-
served in 2 (4%) and 4 (8%) patients, respectively, but did not
necessitate cessation of therapy. Six patients (12%) were anaemic
at baseline and a further two (4%) developed anaemia during
therapy. Elevations in serum alanine amino transferase (ALT) to
above the upper limit of normal (ULN; .40 U/L) occurred in 5
(10%) of patients. However, no patients had criteria under Hy’s
Law for drug induced liver injury (ALT .36ULN together with a
rise in serum bilirubin to .26ULN) [13].
Neutropaenia developed in one patient, a 90-year old male with
infective endocarditis due to Enterobacter cloacae. He had received
meropenem by CI for 43 days before developing a nadir
neutrophil count of 0.066109/L. The neutropaenia resolved on
cessation of meropenem. Nephrotoxicity developed in one patient,
an 86-year old woman with a history of chronic renal impairment
and type-2 diabetes. She was receiving concomitant voriconazole
for malignant otitis externa and was re-admitted to hospital for
side-effects attributed to this antifungal agent. Meropenem, given
by intermittent dosing, was continued in hospital with resolution of
her renal impairment. This patient was also one that developed
anaemia. There were no PICC-related adverse events, infusion
reactions or neurotoxicity, and no patients died during OPAT
therapy.
Meropenem stability under simulated OPAT conditions
A total of 32 infusion devices were prefilled. Three were
excluded from further analysis because the initial concentrations
were .25% expected. The 29 infusers included in the analysis
were grouped as i) 1% w/v, room temperature (n = 6), ii) 2% w/v,
room temperature (n = 7), iii) 1% w/v, cooled (n = 8), and iv) 2%
w/v, cooled (n = 8) infusers. Meropenem recovery over the 24-
hour period is shown (Figure 1). The mean 24-hour recovery,
semi-quantitative temperature measurement and MDD% accord-
ing to group are shown (Table 1). Cooled infusers with 1% w/v
meropenem had a mean stability .90%. However, regardless of
cooling, the 1% w/v infusers would deliver $95% of the MDD
whilst only the 2% w/v infuser at room temperature delivered ,
90% of the MDD. Although the cooling measures increased the
time that the temperature of the infuser was ,20uC (12.3 versus
3.5 hours, P,0.0001), the time ,20uC did not correlate with
meropenem recovery at 24 hours (r2 = 0.04, P = 0.28). There were
no statistically significant differences in median meropenem
recovery at 24 hours between the infuser groups, regardless of
concentration or cooling measures.
To illustrate of the potential effects of degradation on expected
plasma meropenem concentrations in patients receiving continu-
ous infusions, we incorporated population pharmacokinetic
variability as well as our observed degradation to a simulated
model of 70 kg male patients with normal renal function during a
7-day course of meropenem. Median, 2.5th centile and 97.5th
centile plasma concentrations for 1% cooled and 2% room
temperature infusers are shown in Figure 2A and 2B, respectively.
In both simulations the vast majority had plasma concentrations
above the breakpoints for P. aeruginosa and Enterobacteriaceae
(4 mg/L and 1 mg/L, respectively) for 100% of the time.
Discussion
With the progressive emergence of antimicrobial resistance in
Gram-negative bacteria and the increased utilisation of OPAT for
a variety of infections, there is considerable interest in re-
examining the stability and safety of meropenem given by CI
[16]. Our clinical study demonstrates a high rate of clinical
efficacy (82% either cured or improved) with a low frequency of
severe adverse events requiring cessation of therapy (10%). The
present stability data demonstrate that infusers with meropenem at
1% under cooled conditions have a mean recovery at 24 hours
that is equivalent to the traditional stability threshold of 90%.
However, 1% infusers, regardless of cooling and cooled 2%
infusers are likely to deliver close to 95% of the MDD of
meropenem and therefore are likely to maintain effective plasma
concentrations throughout each 24-hour period.
As observed in the present study, patients requiring prolonged
courses of carbapenem antibiotics such as meropenem often have
frequent co-morbidities, severe underlying chronic disease, a
predominance of complex infections involving P. aeruginosa and
resistant Enterobacteriaceae, and frequent concomitant adminis-
tration of other antimicrobial medications. These factors may
contribute to clinical failure and more frequent severe adverse
events, particularly if the duration of therapy is prolonged [16].
Overall, the low frequency of haematologic toxicity (anaemia,
thrombocytopaenia and neutropaenia), nephrotoxicity and/or
hepatotoxicity was less than, or comparable to, that observed
when other beta-lactams are used in the OPAT setting [16]. The
toxicity profile of meropenem infusions in this study also compares
favourably with that of vancomycin, an antibiotic commonly given
by CI in our Western Australian OPAT centres, and which is
associated with nephrotoxicity and neutropaenia occurring in 16%
[17] and 2% [18] of patients, respectively. Our data also compare
favourably with reported neutropaenia rates in patients receiving
prolonged courses of piperacillin-tazobactam for bone infections
[19].
To the best of our knowledge, no other study has examined
24 h meropenem stability in infusion devices at low concentrations
under simulated OPAT conditions using practical cooling
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measures. The infuser devices in the present study were made up
to 240 mL rather than the 100–125 mL used in other infuser
devices [6,7], thereby allowing the same dose to be infused but at
more favourable lower concentrations. The mean recovery of 1%
w/v meropenem carried in a cooled bag was 90% at 24 hours. In
descending order, the mean 24-hour recoveries for infusers
containing 1% w/v uncooled, 2% w/v cooled and 2% w/v room
temperature meropenem were lower than the recommended 90%
threshold (88%, 87% and 83%, respectively). The continuous
temperature data show that, when using the ‘cooled’ bag with ice
pucks changed every 8 hours, the temperature was ,20uC for
approximately half the time versus only ,3 hours in the uncooled
infusers. Although there was no statistically significant correlation
between the time ,20uC and mean meropenem recovery at 24-
Figure 1. Meropenem degradation in elastomeric infusion devices at different conditions over a 24-hour period (data points are
mean values).
doi:10.1371/journal.pone.0102023.g001
Table 1. Meropenem recovery, percentage of maximum deliverable dose and time less than 20uC for 24-hour elastomeric infusion
device at different conditions (data are given as means [Standard Deviations; SD]).
Infusion concentration (w/v),
cooled/uncooled Time ,206C (hours)
Meropenem recovery at
24 hours (% [SD]) Maximum deliverable dose (% [SD])
1%, uncooled 3.68 87.6 (6.1) 96.4 (8.7)
2%, uncooled 3.34 82.9 (7.8) 87.2 (6.6)
1%, cooled 12.14 90.3 (6.5) 95.0 (5.7)
2%, cooled 12.39 87.0 (6.2) 92.9 (3.9)
doi:10.1371/journal.pone.0102023.t001
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Figure 2. Median and 95% prediction intervals (PI95) of simulated plasma meropenem concentrations incorporating degradation as
well as pharmacokinetic variability in 200 simulations of an average, 70 kg male patient receiving meropenem by continuous
infusion in a cooled infuser containing 1% meropenem (figure 2A) and ‘room temperature’ infuser containing 2% meropenem
(figure 2B). Susceptibility breakpoints for Pseudomonas aeruginosa (upper grey dashed line) and Enterobacteriaciae (lower grey dashed line) are also
shown in each.
doi:10.1371/journal.pone.0102023.g002
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hours, meropenem recovery and MDD% were lower for the
infusers that were kept at room temperature. In a comparable
study, infusers containing 3% w/v meropenem were lodged
between two ice-bricks and administered to patients with cystic
fibrosis over 12 h. Continuous temperature measurements were
not made during this study. After 12 h, the infusers remained
cooled and were kept to assess meropenem recovery at 24 hours
[7]. Using this method of infusion, plasma steady state concen-
trations remained well above the target concentrations required to
treat most Gram-negative infections and the meropenem recov-
eries were all .90% after 12 h and in 3 of 4 infusers after 24 h
[20].
Although the mean recovery of meropenem at 24 hours was #
90% in our study, the time-dependent nature of meropenem
degradation may mean that the total drug exposure is adequate to
treat most serious infections. In the present study, we estimated the
percentage of the MDD and found that, regardless of cooling
measures, the patient would receive .95% of the planned dose
with a 1% w/v continuous infusion and 93% and 87% for the 2%
w/v infusers in cooled and room temperature bags, respectively.
The illustrative simulations also demonstrate that adequate
pharmacodynamics targets are likely to be attained in most
patients, regardless of the infecting organism. These simulations
were based on inputs that accounted for degradation during the
infusion and incorporated published population pharmacokinetic
variability for meropenem. They demonstrate that the simulated
median meropenem concentrations of 200 average 70 kg, male
adult patients receiving continuous CIs are above accepted
breakpoints [15] for P. aeruginosa and Enterobacteriaceae 100%
of the time, regardless of the cooling measures undertaken. The
2.5th centile of these simulations also demonstrates that nearly all
patients receiving 2%, uncooled meropenem infusors are also
above both breakpoints for 100% of the time, but indicate that a
small minority of patients receiving 1% infusers may not achieve
concentrations above 4 mg/L for 100% of the time.
The other major factor in determining a safe stability threshold
for meropenem is the potential toxicity of degradation products. A
thermal degradation product (DP1) of meropenem in aqueous
solution following a 36 hour exposure to 45uC has been identified
as 4-methyl-3-(1H-pyrrol-3-ylsulfanyl)-5H-pyrrole-2-carboxylic
acid (MW = 227.1). Few clinical data exist on the possible toxicity
profile of DP1. In the only relevant paper in the literature, a
degraded solution of meropenem had a limited cytopathic effect
on in vitro cultured peripheral blood mononuclear cells at 24 h at
concentrations 0.5–2 mg/mL, but some effect after incubation for
48 and 72 h [21].
Our study had some limitations. The clinical part was
retrospective and therefore the clinical data may not have been
collected in a standardised manner. However, we believe that most
important possible adverse events were captured as the OPAT
clinicians reviewed all patients at least weekly. In addition,
laboratory monitoring was performed at least weekly for all
OPAT patients in a standardised manner. Although we did not
include a control comparator group, the substantial differences in
co-morbidities, microbiological susceptibility of infecting organ-
isms and illness severity (defined by in-patient status), precluded
robust matching of our case patients to possible controls such as
OPAT patients receiving piperacillin/tazobactam by continuous
infusion or to inpatients receiving intermittent infusions of
meropenem. As this was a retrospective study and our laboratory
does not routinely perform meropenem MICs for Gram-negative
organisms, we were unable to adjust our analyses of clinical
outcome according to the infecting pathogen’s MIC. A final
limitation was that the simulations did not account for potential
variability in renal function. In the real world, as demonstrated in
the present case series, renal function may be impaired in patients
with multiple co-morbidities and treated with concomitant
potentially nephrotoxic medications, resulting in decreased clear-
ance of meropenem. Conversely, very sick patients may have
augmented renal clearance and increased drug distribution that
might result in inadequate drug exposure. A formal analysis of
such effects was beyond the scope of the present study, not least
because these very unwell patients with significant pharmacoki-
netic perturbations would not usually be suitable for OPAT.
In summary, the present study demonstrates that infusions with
meropenem at 1% w/v under cooled conditions have a mean
recovery of 90% at 24 hours, a value equivalent to the stability
threshold of 90%. However, 1% w/v solutions regardless of
cooling and cooled 2% w/v solutions deliver close to 95% of the
MDD. Simulated data that incorporates population pharmacoki-
netic variability as well as the degradation observed also
demonstrate that for the majority of patients, meropenem
concentrations will be maintained above the breakpoints for
Enterobacteriaceae and Pseudomonas aeruginosa for 100% of the
time.
Although these results accord with the favourable clinical
experience at our institutions and are reassuring because adequate
drug concentrations are likely to be attained, further studies are
required to confirm the safety and efficacy of meropenem CIs.
Ideally, future studies should be prospective with pre-defined
assessments of toxicity and efficacy outcomes. Meropenem and
possible toxic degradation products should also be measured in
patient plasma samples.
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